Lutetium Lu-177

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lutetium Lu-177
DrugBank Accession Number
DB13982
Background

Not Available

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 176.9438
Monoisotopic: 176.943754987
Chemical Formula
Lu
Synonyms
  • 177Lu
  • Lu 177
  • Lu-177
  • Lutetium-177

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Diagnostic agentNeuroendocrine tumour••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Lutetium chloride Lu-1771U477369SN16434-14-3AEDROEGYZIARPU-SUNKFXMWSA-K
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Endolucinbeta40 GBq/mLItm Medical Isotopes Gmb H2016-09-08Not applicableEU flag
Endolucinbeta40 GBq/mLItm Medical Isotopes Gmb H2016-09-08Not applicableEU flag
Illuzyce51.8 GBq/mlBillev Pharma Aps2022-12-05Not applicableEU flag
Illuzyce51.8 GBq/mlBillev Pharma Aps2022-12-05Not applicableEU flag
Illuzyce51.8 GBq/mlBillev Pharma Aps2022-12-05Not applicableEU flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous lanthanide compounds. These are inorganic compounds containing only metal atoms, with the largest atom being a lanthanide atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous lanthanide compounds
Sub Class
Not Available
Direct Parent
Homogeneous lanthanide compounds
Alternative Parents
Not Available
Substituents
Homogeneous lanthanide
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
BRH40Y9V1Q
CAS number
14265-75-9
InChI Key
OHSVLFRHMCKCQY-NJFSPNSNSA-N
InChI
InChI=1S/Lu/i1+2
IUPAC Name
(177Lu)lutetium
SMILES
[177Lu]

References

General References
Not Available
ChemSpider
141480

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentCastration-Resistant Prostate Carcinoma / Stage IVB Prostate Cancer AJCC v81
4RecruitingOtherProstate Cancer1
3Active Not RecruitingTreatmentMetastatic Castration-Resistant Prostate Cancer (mCRPC)1
3Active Not RecruitingTreatmentNeuroendocrine Tumors1
3Not Yet RecruitingTreatmentNeuroendocrine Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravenous40 GBq/ml
SolutionOther40 GBq/ml
SolutionOther80 GBq/ml
SolutionIntravenous80 GBg/mL
SolutionIntravenous97 GBq
Solution40 GBq/ml
SolutionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count0Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area0 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity0 m3·mol-1Chemaxon
Polarizability1.78 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at January 20, 2018 19:24 / Updated at February 13, 2021 11:02